Sunday, December 28, 2014 Last update: Yesterday, 8:03 AM - Covering Large & Obscure Tech Companies Since 1996

SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures

Companies mentioned in this article: Sangui BioTech International, Inc.

WITTEN, Germany -- (BUSINESS WIRE) -- According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of USD42,000 in the course of the fourth quarter of its financial year 2014, ended June 30, 2014. In the third quarter (ended March 31, 2014) revenues had amounted to USD29,438; in the fourth quarter of its financial year 2013 (ended June 30, 2013) the company reported revenues of USD24,056. Based on this preliminary state of accounting Sangui will presumably present revenues of more than USD130,000 for its 2014 financial year (FY 2013: USD105,487).

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace ( SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Copyright © Business Wire 2014

For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
Sangui BioTech International, Inc.
291 South 200 West
P.O. Box 832
Farmington, Utah 84025
c/o SanguiBioTech GmbH
Alfred-Herrhausen-Str. 44
58455 Witten